JP2008516970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516970A5 JP2008516970A5 JP2007536935A JP2007536935A JP2008516970A5 JP 2008516970 A5 JP2008516970 A5 JP 2008516970A5 JP 2007536935 A JP2007536935 A JP 2007536935A JP 2007536935 A JP2007536935 A JP 2007536935A JP 2008516970 A5 JP2008516970 A5 JP 2008516970A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- region
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102100025221 CD70 antigen Human genes 0.000 claims 16
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 16
- 239000012636 effector Substances 0.000 claims 9
- 208000026278 immune system disease Diseases 0.000 claims 9
- 239000011230 binding agent Substances 0.000 claims 8
- 230000001085 cytostatic effect Effects 0.000 claims 8
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000000824 cytostatic agent Substances 0.000 claims 7
- 231100000433 cytotoxic Toxicity 0.000 claims 6
- 230000001472 cytotoxic effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 230000001506 immunosuppresive effect Effects 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61901804P | 2004-10-15 | 2004-10-15 | |
| US60/619,018 | 2004-10-15 | ||
| US64535505P | 2005-01-19 | 2005-01-19 | |
| US60/645,355 | 2005-01-19 | ||
| PCT/US2005/036994 WO2006044643A2 (en) | 2004-10-15 | 2005-10-14 | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012162676A Division JP2012197321A (ja) | 2004-10-15 | 2012-07-23 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008516970A JP2008516970A (ja) | 2008-05-22 |
| JP2008516970A5 true JP2008516970A5 (enExample) | 2008-11-06 |
| JP5222559B2 JP5222559B2 (ja) | 2013-06-26 |
Family
ID=36203547
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536935A Expired - Lifetime JP5222559B2 (ja) | 2004-10-15 | 2005-10-14 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
| JP2012162676A Withdrawn JP2012197321A (ja) | 2004-10-15 | 2012-07-23 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012162676A Withdrawn JP2012197321A (ja) | 2004-10-15 | 2012-07-23 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US7491390B2 (enExample) |
| EP (1) | EP1799262A4 (enExample) |
| JP (2) | JP5222559B2 (enExample) |
| AU (1) | AU2005295595C1 (enExample) |
| CA (1) | CA2583208C (enExample) |
| WO (1) | WO2006044643A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58103228A (ja) * | 1981-12-16 | 1983-06-20 | Kaga Tsushin Kogyo Kk | 光スイツチ方法 |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| EP1799262A4 (en) | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS |
| US7641903B2 (en) * | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US8337838B2 (en) * | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| EP2511299A1 (en) | 2005-04-19 | 2012-10-17 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
| AU2006269422B2 (en) | 2005-07-07 | 2012-12-06 | Seagen Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
| CA2623236A1 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| ES2523915T5 (es) * | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| US20100150950A1 (en) * | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| CN110372795A (zh) | 2007-08-02 | 2019-10-25 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
| DK2276509T3 (en) * | 2008-04-11 | 2016-09-19 | Seattle Genetics Inc | DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers |
| CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| RU2012110585A (ru) | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Каталичические домены лизилоксидазы и loxl2 |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| CA2712747A1 (en) * | 2010-08-11 | 2012-02-11 | Universite De Montreal | Combinatory cancer treatment |
| AR083214A1 (es) * | 2010-09-29 | 2013-02-06 | Genentech Inc | Composiciones de anticuerpo anti complejo i de hcmv y metodos de uso |
| KR101847523B1 (ko) | 2011-01-24 | 2018-05-28 | 연세대학교 산학협력단 | 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 |
| CA2828753C (en) | 2011-03-16 | 2022-07-26 | arGEN-X BV | Antibodies to cd70 |
| CA2845884A1 (en) | 2011-08-22 | 2013-02-28 | Cangene Corporation | Clostridium difficile antibodies |
| ES2806146T3 (es) * | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| AU2012327223A1 (en) * | 2011-11-30 | 2013-06-20 | Wellstat Diagnostics, Llc. | Assays, antibodies, immunogens and compositions related to 5-FU |
| HUE045435T2 (hu) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pirrolobenzodiazepinek és konjugátumaik |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| ES2774976T3 (es) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
| CA2921639A1 (en) | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| EP3487522A4 (en) | 2016-07-19 | 2020-04-01 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| CN110352074B (zh) | 2017-02-28 | 2024-07-16 | 思进股份有限公司 | 用于偶联的半胱氨酸突变抗体 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| MY201573A (en) | 2017-05-12 | 2024-03-02 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| PE20251579A1 (es) * | 2018-02-01 | 2025-06-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
| CN112020518A (zh) | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
| JP7542441B2 (ja) | 2018-05-11 | 2024-08-30 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 癌を治療するための方法及び組成物 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| TWI877278B (zh) | 2019-12-30 | 2025-03-21 | 美商思進公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| CA3185846A1 (en) | 2020-06-30 | 2022-01-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd70 antibody and application thereof |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| AU2021377699A1 (en) | 2020-11-13 | 2023-06-15 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| AU2021388155A1 (en) | 2020-11-25 | 2023-06-15 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN117203238A (zh) | 2021-04-23 | 2023-12-08 | 普方生物制药美国公司 | Cd70结合剂、其偶联物及其使用方法 |
| CA3236930A1 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| EP4507779A1 (en) | 2022-04-14 | 2025-02-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| US7442776B2 (en) | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| EP1358349A2 (en) | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| AU2002306651B2 (en) * | 2001-03-02 | 2007-12-13 | Medimmune, Llc | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists |
| US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) * | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US7261892B2 (en) * | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| WO2003046581A2 (en) * | 2001-11-27 | 2003-06-05 | Oxford Glycosciences (Uk) Ltd | Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers |
| DE10231126A1 (de) | 2002-07-10 | 2004-02-05 | Daimlerchrysler Ag | Verfahren zum Starten eines Gaserzeugungssystems |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| WO2004073656A2 (en) * | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| AU2003237076A1 (en) | 2003-05-23 | 2004-12-13 | Stichting Sanquin Bloedvoorziening | Therapeutical use of anti-cd70 antibody for treating or preventing aids |
| US20050282168A1 (en) | 2003-09-29 | 2005-12-22 | Wyeth | Cell surface molecules as markers and therapeutic agents against kidney cancers |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005077462A2 (en) * | 2004-02-09 | 2005-08-25 | The Cbr Institute For Biomedical Research, Inc. | Cd70 inhibition for the treatment and prevention of inflammatory bowel disease |
| CN101010179A (zh) | 2004-08-05 | 2007-08-01 | 富士胶片株式会社 | 用于制造涂料的设备 |
| US7337958B2 (en) * | 2004-10-04 | 2008-03-04 | Hewlett-Packard Development Company, L.P. | Calculator device having a USB connection |
| US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| EP1799262A4 (en) | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS |
| US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| EP2511299A1 (en) | 2005-04-19 | 2012-10-17 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
| CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
-
2005
- 2005-10-14 EP EP05814787A patent/EP1799262A4/en not_active Withdrawn
- 2005-10-14 JP JP2007536935A patent/JP5222559B2/ja not_active Expired - Lifetime
- 2005-10-14 WO PCT/US2005/036994 patent/WO2006044643A2/en not_active Ceased
- 2005-10-14 US US11/251,173 patent/US7491390B2/en active Active
- 2005-10-14 AU AU2005295595A patent/AU2005295595C1/en not_active Ceased
- 2005-10-14 CA CA2583208A patent/CA2583208C/en not_active Expired - Lifetime
-
2008
- 2008-01-18 US US12/016,848 patent/US20080138343A1/en not_active Abandoned
- 2008-01-18 US US12/016,814 patent/US8647624B2/en active Active
- 2008-11-05 US US12/265,451 patent/US9051372B2/en active Active
-
2012
- 2012-07-23 JP JP2012162676A patent/JP2012197321A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516970A5 (enExample) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2011520898A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2020023523A5 (enExample) | ||
| JP2016505556A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2009506791A5 (enExample) | ||
| JP2014039548A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2017526370A5 (enExample) | ||
| JP2020527144A5 (enExample) | ||
| JP2019512464A5 (enExample) | ||
| JP2019509055A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2010533498A5 (enExample) | ||
| JP2019525728A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| WO2006003407A3 (en) | Chimeric and humanised monoclonal antibodies against inteleukin- 13 | |
| JP2012500020A5 (enExample) | ||
| JP2010532764A5 (enExample) |